Improved understanding of the therapeutic potential of the immune system has led to considerable progress in the field of immunotherapy for the treatment of several cancers. The efficacy of allogeneic stem cell transplant, the first example of cancer immunotherapy, is largely mediated by the donor immune cells (the GvL effect). Efforts to selectively manipulate components of immune system has led to development of immune checkpoint blockade-targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1), immunomodulatory drugs and adoptive cellular therapy including chimeric Ag receptor T cell (CAR T cell). Programmed death 1(PD-1),is an immune checkpoint receptor present on T cells, B cells and myeloid cells. 1 Engagement of PD-1 by one of its ligands, PD-L1 or PD-L2, leads to decreased T-cell proliferation, cytotoxicity and increased susceptibility to apoptosis. 1 Overexpression of PD-L1 is seen in several cancers and is considered to have a role in 'immune escape'.
2 Some cancers also show significant lymphocyte infiltration with an increased expression of PD-1 on their surface. 3 Blockade of the PD-1-PD-L1 axis has been shown to enhance antitumor response in various clinical trials. 4 Initially limited to solid tumors, a large number of clinical trials are now looking at the efficacy of these drugs in hematological malignancies. Hodgkin's lymphoma presents a unique target, as tumor cells often display amplification of chromosome 9p24.1, which leads to overexpression of PD-L1 through activation of the Janus kinase signal transducer and activator of transcription pathway. 5 These characteristic Reed-Sternberg cells reside in a milieu of an extensive but ineffective T-cell infiltrate. 6 EBV is often associated with Hodgkin's lymphoma and causes overexpression of PD-L1 on tumor cells. 7 PD-1 inhibitors nivolumab and pembrolizumab have both been studied in relapsed Hodgkin's lymphoma with promising initial results. 8, 9 Only limited data are available for the use of these drugs after transplant where relapse continues to be a challenge. It also presents a unique environment to study the effects of these drugs. In a phase II study, use of an anti-PD-1 monoclonal Ab in patients with diffused large B-cell lymphoma after an autologous stem cell transplant was associated with mild toxicity and good overall safety profile. 10 There are limited available data regarding the use of these drugs in the post-allogeneic transplant setting as these patients are generally excluded from clinical trials.
11 Blocking of PD-1/PD-L1 pathway could potentially enhance the T-cell-mediated graft-versus-tumor effect, but it could also potentially cause significant GvHD. 12 In a recent report, a single dose of nivolumab led to CR in a patient who relapsed after an allogeneic transplant. 13 We report a case of fatal GvHD induced by PD-1 inhibitor pembrolizumab in a Hodgkin's lymphoma patient.
A 29-year-old man was originally diagnosed with stage II Hodgkin's lymphoma (nodular sclerosis type) and underwent chemotherapy with ABVD (adrimaycin, bleomycin, vinblastine, dacarbazine) ( Figure 1 ). He relapsed and was treated with ICE (ifosfamide, carboplatin, etoposide) followed by an autologous stem cell transplant using BEAM (carmustine, etoposide. cytarabine, melphalan) conditioning. One year later, he received anti-CD30 immunotoxin brentuximab vedotin for another relapse, and then underwent a fludarabine-TBI (Flu 30 mg/m 2 3, TBI: 200 cGy)-based non-myeloablative allogeneic stem cell transplant using a HLA 10/10-matched sibling donor. His post-transplant course was complicated by the development of chronic GvHD involving skin and lungs, which responded to systemic steroids. His disease relapsed 1 year later, which was treated again with brentuximab vedotin for six cycles and went into remission. He had a second relapse 6 months post allogeneic transplant. The patient then sought a second opinion at another institution. He was not eligible for available clinical trials because of the history of allogeneic transplant. After a discussion about the potential risks and benefits, he decided to receive off-label PD-1 inhibitor pembrolizumab outside of a clinical trial. At the time of receiving pembrolizumab, he did not have any signs or symptoms of active GvHD and was not on systemic steroids. One week after receiving the first dose of the drug, he developed abdominal pain with computed tomography scan showing mild colitis, which was managed conservatively. Two weeks after receiving the drug, the patient developed a maculopapular skin rash involving his face, upper chest and back. This rash was accompanied by worsening diarrhea and a rise in liver function tests with total bilirubin going up to 446.1 μmol/L (normal range, 5.13-20.52 μmol/L), aspartate transaminase 5.93 μkat/L (normal range 0.17-0.51 μkat/L), alanine transaminase 21.44 μkat/L (normal range, 0.17-0.68 μkat/L) and alkaline phosphatase rising up to 7.28 μkat/L (0.5-2 μkat/L). Skin, gastrointestinal (GI) and liver biopsies were performed to rule out other causes like drug reaction. Liver biopsy showed mixed portal inflammation, bile duct lymphocytic infiltration, epithelial damage and portal vein endotheliitis, consistent with GvHD. Skin biopsy revealed vacuolar interface dermatitis with solitary and short zones of confluent keratinocyte apoptosis, also consistent with GvHD. Upper and lower GI biopsies were inconclusive. Overal, GvHD was graded as stage IV skin, stage II gut and stage IV liver leading to an overall grade IV acute GvHD. Patient was started on 2 mg/kg of methylprednisolone along with topical steroids for skin, liver and GI tract involvement. He did not have a response and required second-line therapy for GvHD with basiliximab and subsequently anti-thymocyte globulin (ATG). He continued to have progressive GvHD with worsening liver failure, development of coagulopathy and altered mental status. A positron emission tomography scan was done 6 weeks after pembrolizumab dose and showed no areas of active lymphoma. He ultimately died of respiratory failure secondary to pneumonia at 8 weeks after pembrolizumab dose.
T-cell co-stimulatory pathways including CTLA-4 and PD-1 have a crucial role in maintaining a delicate balance between protective immunity and tolerance. Deficiencies in both CTLA-4 and PD-1 pathways have been shown to result in an autoimmune phenotype.
1 CTLA-4 is considered to act early during T-cell activation, whereas PD-1 pathway influences sites distal to initial activation.
14 The PD-1:PD-L pathway provides the inhibitory signals required for regulation of both central and peripheral T-cell tolerance. Because of the critical role T cells have in the pathogenesis of GvHD, several studies have investigated the role of PD-1/PD-L1 pathway. Blazar et al. 15 performed experiments in mice to evaluate the effect of PD-1 blockade using anti-PD-1 monoclonal Ab, PD-L1.Fc protein (mutated murine IgG2a Fc portion)and PD-1 − / − donor cells. They showed that the PD-1 pathway is a negative regulator of both CD4 + and CD8 + T-cell alloresponses. PD-1 blockade enhanced the lethality of GvHD, which was mediated by enhanced release of inflammatory cytokines like interferon-γ and was not dependent upon perforin/FasL-mediated cytolysis. Interestingly, blockade of CTLA--4:B7 pathway further hastened the GvHD, thus supporting a nonredundant role of CTLA-4 and PD-1 in GvHD. Of the two PD-1 ligands, PD-L1 has a broader expression pattern and is constitutively present in T and B cells, macrophages, mesenchymal stem cells as well as non-hematopoietic cells like liver parenchymal cells and pancreatic islets. 16 PD-L2 is expressed on dendritic cells, macrophages and bone marrow-derived mast cells. Saha et al. 17 demonstrated the critical importance of PD-1/PD-L1, but not PD-1/ PD-L2 pathway in the regulation of GvHD. In a murine model, they demonstrated the enhanced expression of PD-L1 ligand in target tissues during acute GvHD. However, blockade of PD-1/PD-L1, but not PD-1/PD-L2 enhanced GvHD-induced lethality that was accompanied by increased proliferation, cytokine production and metabolic stress of donor T cells. This increase in T-cell activity was preferentially noted in GvHD target organs like colon and ileum where a loss of epithelial cell integrity was observed. 17 In addition to PD-1, PD-L1 also binds to CD80 on the surface of T cells. Using an alloimmune model of GvHD, Deng et al. 18 showed that outcome of PD-L1/CD80 interaction is influenced by the presence or absence of PD-1. In the absence of PD-L1/PD-1 interaction, PD-L1/CD80 augments alloreactive T-cell proliferation leading to worsening GvHD. This provides an additional mechanism of how PD-1 blockade could cause worsening GvHD mortality. Amarnath et al. 19 showed that PD-L1 caused human Th1 cells to convert into T reg cells both in vitro and in vivo resulting in inhibition of GvHD. In this experiment, restoration of GvHD was achieved by blocking PD-1 or by pharmacological inhibition of SHP1/SHP2, which are signaling molecules downstream to PD-1 receptor.
To our knowledge, this is the first reported case of fatal GvHD induced by pembrolizumab in humans. As the indications for use of this class of drugs continue to expand, one should be aware of the potential toxicities in different clinical settings. Several other questions remain unanswered. How do these drugs influence post autologous transplant immune reconstitution?, How does the pretransplant use of these drugs alter the post-transplant course in the setting of allogeneic transplant?, When to stop them prior to starting the conditioning regimen? and How to use biomarker expression as a guide to predict response? We will have to wait for the mature data from the current trials and new trials to answer these questions. As GvHD is often accompanied by graft-vs-tumor effect, PD-1 inhibitors could still have a role in post-transplant relapse, but more studies need to be done to optimize the timing, duration and dosing of these drugs.
